Safety, efficacy, and drug survival of the infliximab biosimilar CT‐P13 in post‐marketing surveillance of Japanese patients with psoriasis

Morita, Akimichi; Nishikawa, Kiyohiro; Yamada, Fumika; Yamanaka, Keiichi; Nakajima, Hideki; Ohtsuki, Mamitaro

doi:10.1111/1346-8138.16508

Public

Safety, efficacy, and drug survival of the infliximab biosimilar CT‐P13 in post‐marketing surveillance of Japanese patients with psoriasis

Published in The Journal of Dermatology • Jul 7, 2022

Authors:

Akimichi Morita

Kiyohiro Nishikawa

Fumika Yamada

Abstract

Based on extrapolation of similar clinical outcomes in rheumatoid arthritis to the originator infliximab (IFX) in randomized clinical trials, the first biosimilar antibody CT-P13 was approved for the treatment of psoriasis. To evaluate the safety, efficacy, and drug survival of CT-P13 for psoriasis ...

Subject

Medicine

Psoriasis

Psoriatic arthritis

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!